Supply Chain
Assessment for CGT

Cell and gene therapies are distinctly different from traditional biopharma product and their supply chains require uniquely designed logistics solutions for optimal patient delivery and administration.

Helping you address complex supply chain challenges

 

Materials produced for autologous and allogeneic therapies must be shipped under strict temperature controls within extremely tight timelines, and with full traceability always. HiTech Health can help you address complex supply chain challenges and provide end-to-end assistance with managing all aspects to ensure the products are manufactured and supplied to patients efficiently and effectively.

HiTech Health can assist you with:

 

  • Day-to-day management of supply chain activities.
  • Coordination between CMOs, treatment centres and logistics providers.
  • Supply chain risk assessments and mitigation plans.
  • Selection of supply chain vendors.
  • Evaluation of CGT supply chain and improvements.
  • Responsible Person (RP) services for CGT.

Cell and Gene Therapy Manufacturing

HiTech Health are delighted to have an article entitled 'Cell and Gene Therapy Manufacturing Considerations for Early Stage Companies' published in distinguished publications, cellandgene.com and outsourcedpharma.com. The article should be of benefit to companies who...

2024 ATMP Review

Over the past decade, the regenerative medicine landscape has undergone an extraordinary evolution with the continuous growth of Advanced Therapeutic Medicinal Products (ATMPs). ATMPs are medicines for human use that are based on genes, tissues or cells. They treat...

Contact us

Get in touch anytime – we are always available to discuss your upcoming projects.